Halozyme Therapeutics | HALO - El Costo De Ventas

Precio De Mercado
66.37
Cambio Diario
0.50 0.76%
Mensual
4.36%
Anual
-5.38%
Q2 Expectativa
62.63




El Costo De Ventas Cambio Fecha
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Amarin USD 26.05M 1.41M 2025-12
Amgen USD 1.6B 187M 2026-03
Baxter International USD 1.81B 587M 2026-03
Cara Therapeutics USD 0 0 2025-03
Cytokinetics USD 160K 104.24M 2026-03
Eli Lilly USD 3.58B 205M 2026-03
Esperion Therapeutics USD 27.85M 13.43M 2025-12
Halozyme Therapeutics USD 102.15M 29.14M 2025-12
Intrexon USD 1.01M 344K 2024-06
Ionis Pharmaceuticals USD 3M 5M 2026-03
MannKind USD 33.65M 13.44M 2025-12
Minerva Neurosciences 386K 31K 2024-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Pfizer USD 4.59B 1.7B 2026-03
Rigel Pharmaceuticals USD 8.03M 5.22M 2024-09
United Therapeutics USD 474.7M 373.8M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12